The firm's principle focus is in the therapeutic potential of drugs targeting the aberrant biological activity of the HOX family of genes that occurs in many cancers, and which is the area of expertise of its co-founders, Professor Hardev Pandha and Professor Richard Morgan, respectively a medical oncologist and molecular biologist.